Search Results

Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded LDL-C lowering in both primary and secondary prevention patients.

Esperion bagged broader-than-expected FDA labels for its cholesterol-busting drugs Friday, allowing the biotech to target seven times as many people in the U.S. compared to the old labels.

Wednesday’s settlement resolves a legal dispute between Daiichi Sankyo Europe and Esperion Therapeutics regarding milestone payments under their cardiovascular drug collaboration.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

For Daiichi Sankyo, recent results from the Phase III CLEAR trial of Esperion Therapeutics’ Nexletol (bempedoic acid) were not convincing enough to trigger a milestone payment.

Gain Therapeutics, Inc. announces that Matthias Alder has departed the Company in order to pursue other opportunities.

Initiates Development of Tailored Innovative Targeted Therapy for Refractory Cancer ReCerise Therapeutics Inc., has announced its selection for a grant from the Ministry of Trade, Industry and Energy of South Korea.

Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced plans to accelerate its development initiatives in obesity and cardiometabolic disease through the acquisition of the assets of Better Therapeutics, Inc.